NRBO Live signaler | Maksimer profitt med Getagraph.com

KJøP 111306 min ago

@ $4.65

Utstedt: 14 feb 2024 @ 21:13

Avkastning: -20.86%

Forrige signal: feb 12 - 15:45

Forrige signal: Selg

Avkastning: -4.12 %

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 22:00):

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases...

Stats
Dagens volum	60 008.00
Gjennomsnittsvolum	246 172
Markedsverdi	18.05M
EPS	$-2.28 ( 2024-04-04 )
Neste inntjeningsdato	( $-0.950 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.500
ATR14	$0.0310 (0.84%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Woodworth Marshall H	Buy	33 496	Common Stock
2023-12-01	Tursi James Patrick	Buy	7 157	Common Stock
2023-12-01	Tursi James Patrick	Buy	25 000	Common Stock
2023-11-01	Tursi James Patrick	Buy	0
2023-10-27	Woodworth Marshall H	Buy	0

INSIDER POWER
33.97
Last 74 transactions
Buy: 14 405 360 \| Sell: 2 893 741

Neurobo Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Neurobo Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$7 000.00
Bruttogevinst:	$0 (0.00 %)
EPS:	$-2.46

FY	2023
Omsetning:	$7 000.00
Bruttogevinst:	$0 (0.00 %)
EPS:	$-2.46

FY	2022
Omsetning:	$0
Bruttogevinst:	$-28 000.00 (0.00 %)
EPS:	$-19.01

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-28.27

Financial Reports:

No articles found.

Neurobo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.